Teranode Launches Industry's First Model-driven LIMS for the Life Sciences
TERANODE XDA Extended with LIMS Functionality that Transforms Experiment Designs into Automation without Programming, Improves Lab Flexibility and Efficiency
SEATTLE, Wash. -- June 13, 2005 -- Teranode Corporation, the leading innovator of experiment design automation (XDA) software for the Life Sciences industry, today announced the release of TERANODE XDA 2.7, its next-generation model-driven informatics platform and the industry's first model-driven LIMS to transform experiment designs into automation without programming. The new LIMS extensions provide a more cost-effective solution for lab automation compared to traditional methodologies, such as standard databases or spreadsheets. (See also today's press release entitled, "Teranode Improves Lab Flexibility and Efficiency with Launch of New Screening Automation Solution.")
"Model-driven informatics is a significant leap forward, technologically speaking, in the way life science R&D professionals handle data and experiments," said Michael Elliot, principal analyst for Atrium Research. "With model-driven informatics, the effort and time to automate lab procedures can be significantly reduced with the added advantage of streamlining collaboration and enabling a semantically rich web of data."
TERANODE XDA automates data management, flow, and analytics in the lab. The TERANODE XDA platform is comprised of:
- TERANODE Design Suite, a graphical design and automation tool,
- TERANODE Model Server, a common repository for labs, and
- TERANODE Integration, off-the-shelf integration to 3rd party products.
TERANODE XDA 2.7: Model-driven LIMS Extensions
TERANODE XDA 2.7 provides a new LIMS application that automates lab protocols without programming, providing the most flexible and cost-effective LIMS solution for life science labs. TERANODE XDA 2.7 includes:
- Enhanced TERANODE Design Suite (TDS) Protocol Modeler
TDS Protocol Modeler is a visual designer and data manager for lab protocols, allowing scientists to schematically design protocols parameters, measurements, computations, and analytics. TDS Protocol Modeler has been enhanced to capture automation designs, design broader types of reports, and specify dynamic plate reformatting. All designs created in TDS Protocol Modeler are stored as protocol models. - New TDS Protocol Player
TDS Protocol Player is a new application that transforms protocol designs created in TDS Protocol Modeler into an automated LIMS application without programming. TDS Protocol Player reads the protocol models and dynamically constructs wizards that guide lab personnel through the execution of a protocol. TDS Protocol Player automates all the data management, flow, and analytic functions defined in the design. - Enhanced Collaboration
TDS Protocol Player and TDS Protocol Modeler leverage VLX, an XML format, allowing automation with or without a database. Now collaborators can remotely execute experiments and share data without having to rely on a central database or error-prone spreadsheets. - Platform Improvements
TERANODE XDA 2.7 also includes a broad range of improvements to existing features including an improved property panel, layout improvements, new printing features, simplified import/export, and new dynamic data set creation.
"By incorporating LIMS into our award-winning technology, we've created the only informatics software the supports the entire lifecycle of experimentation," said Joseph Duncan, CEO of Teranode. "TERANODE XDA's model-driven platform eliminates programming costs associated with lab automation allowing labs to put their investment in science rather than database development."
Pricing and Availability
Available immediately, pricing for TERANODE XDA begins at $1,000 per user and $25,000 per server. For additional pricing information, please email sales@teranode.com.
About Teranode Corporation
Teranode Corporation, headquartered in Seattle, WA, is the leading innovator of experiment design automation (XDA) software to improve speed and quality of experimentation for the benefit of accelerated R&D. The company, founded in 2002 to revolutionize the role that computing plays in Life Sciences, began with technologies invented by the founders at the University of Washington. TERANODE XDA is being used by leading pharmaceutical, biotechnology, research, and academic organizations including Pfizer, AstraZeneca, and Fred Hutchinson Cancer Research Center.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
